Transce3nd’s Ginkgo Bioworks DNA Stock Holding History

Transce3nd’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-293	Closed	-$3.3K	–	406
2025 Q2	$3.3K	Hold	293	–	–	﹤0.01%	815
2025 Q1	$1.67K	Buy	+293	New	+$2.98K	﹤0.01%	884

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Transce3nd's DNA Position: Q3 2025 in Review

Transce3nd sold out of Ginkgo Bioworks (DNA) in Q3 2025, closing a stake of 293 shares — an estimated $3.3K sold.

Transce3nd first reported a position in DNA in Q1 2025 and held it in 2 quarters. The position peaked at $3.3K in Q2 2025. 174 funds tracked by Wall St. Rank hold DNA as of Q3 2025.

Transce3nd reported no remaining Ginkgo Bioworks position as of Q3 2025 after selling out during the quarter.
Transce3nd sold 293 Ginkgo Bioworks shares in Q3 2025, an estimated $3.3K.
Transce3nd first reported a position in Ginkgo Bioworks in Q1 2025 and held it in 2 quarters.
Transce3nd's Ginkgo Bioworks position peaked at $3.3K in Q2 2025.
174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2025.

Based on Transce3nd's 13F filing for Q3 2025, filed 12 Nov 2025.